Amgen (AMGN) Current Assets (2009 - 2026)
Amgen's quarterly Current Assets came in at $31.5 billion in Q1 2026, up 16.88% year-on-year from $26.9 billion in Q1 2025, and up 8.32% quarter-over-quarter from $29.1 billion in Q4 2025.
Amgen has reported Current Assets for 18 years, with the latest figure at $31.5 billion in Q1 2026.
- For the quarter ending Q1 2026, Current Assets rose 16.88% year-over-year to $31.5 billion; the trailing twelve-month figure through Mar 2026 stood at $31.5 billion (up 16.88% YoY), and the FY2025 full-year result was $29.1 billion, changed 0.09% from the prior year.
- Current Assets for Q1 2026 stood at $31.5 billion, up from $29.1 billion in the prior quarter.
- The five-year high for Current Assets was $48.5 billion in Q3 2023, with the low at $18.5 billion in Q1 2022.
- Average Current Assets over 5 years is $29.9 billion, with a median of $27.9 billion recorded in 2025.
- Year-over-year, Current Assets jumped 145.21% in 2023 and slumped 44.79% in 2024.
- Tracing AMGN's Current Assets over 5 years: stood at $22.2 billion in 2022, then jumped by 36.72% to $30.3 billion in 2023, then dropped by 4.29% to $29.0 billion in 2024, then rose by 0.09% to $29.1 billion in 2025, then climbed by 8.32% to $31.5 billion in 2026.
- The last three Current Assets figures came in at $31.5 billion (Q1 2026), $29.1 billion (Q4 2025), and $27.9 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 54.84 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 59.17 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 33.53 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 35.02 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 31.48 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 18.64 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 42.82 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 27.21 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 23.29 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 31.48 Bn |
| Dec 31, 2025 | 29.06 Bn |
| Sep 30, 2025 | 27.89 Bn |
| Jun 30, 2025 | 26.73 Bn |
| Mar 31, 2025 | 26.93 Bn |
| Dec 31, 2024 | 29.03 Bn |
| Sep 30, 2024 | 26.77 Bn |
| Jun 30, 2024 | 27.21 Bn |
| Mar 31, 2024 | 28.03 Bn |
| Dec 31, 2023 | 30.33 Bn |
| Sep 30, 2023 | 48.48 Bn |
| Jun 30, 2023 | 47.38 Bn |
| Mar 31, 2023 | 44.70 Bn |
| Dec 31, 2022 | 22.19 Bn |
| Sep 30, 2022 | 24.06 Bn |
| Jun 30, 2022 | 19.32 Bn |
| Mar 31, 2022 | 18.52 Bn |
| Dec 31, 2021 | 19.39 Bn |
| Sep 30, 2021 | 24.38 Bn |
| Jun 30, 2021 | 19.10 Bn |
| Mar 31, 2021 | 21.30 Bn |
| Dec 31, 2020 | 21.14 Bn |
| Sep 30, 2020 | 22.66 Bn |
| Jun 30, 2020 | 22.90 Bn |
| Mar 31, 2020 | 18.81 Bn |
| Dec 31, 2019 | 18.44 Bn |
| Sep 30, 2019 | 31.05 Bn |
| Jun 30, 2019 | 30.75 Bn |
| Mar 31, 2019 | 35.15 Bn |
| Dec 31, 2018 | 37.62 Bn |
| Sep 30, 2018 | 38.32 Bn |
| Jun 30, 2018 | 37.97 Bn |
| Mar 31, 2018 | 40.69 Bn |
| Dec 31, 2017 | 49.48 Bn |
| Sep 30, 2017 | 49.75 Bn |
| Jun 30, 2017 | 48.44 Bn |
| Mar 31, 2017 | 46.46 Bn |
| Dec 31, 2016 | 46.01 Bn |
| Sep 30, 2016 | 45.84 Bn |
| Jun 30, 2016 | 42.95 Bn |
| Mar 31, 2016 | 42.21 Bn |
| Dec 31, 2015 | 38.52 Bn |
| Sep 30, 2015 | 38.84 Bn |
| Jun 30, 2015 | 37.74 Bn |
| Mar 31, 2015 | 35.06 Bn |
| Dec 31, 2014 | 34.71 Bn |
| Sep 30, 2014 | 36.05 Bn |
| Jun 30, 2014 | 34.33 Bn |
| Mar 31, 2014 | 28.30 Bn |
| Dec 31, 2013 | 27.37 Bn |
| Sep 30, 2013 | 30.68 Bn |
| Jun 30, 2013 | 29.67 Bn |
| Mar 31, 2013 | 28.70 Bn |
| Dec 31, 2012 | 31.21 Bn |
| Sep 30, 2012 | 32.61 Bn |
| Dec 31, 2011 | 27.59 Bn |
| Mar 31, 2010 | 19.81 Bn |
| Dec 31, 2009 | 18.93 Bn |
| Sep 30, 2009 | 19.97 Bn |
| Jun 30, 2009 | 17.70 Bn |